The present invention provides formulations comprising: L-threonine; Glycine; L-phenylalanine; DL-phenylalanine; Glutamine; NAD; and Magnesium, for use in the treatment of different types of addictions, such as: psychotropic medications, illicit drugs, tobacco and alcohol including, for example, but not limited to, narcotics, benzodiazepines, marijuana, cocaine, methamphetamines, antidepressants, and antipsychotics. The formulations of the present invention promote a detoxification process which facilitates that the brain repairs the damage caused by the abuse of addictive substances.

In some embodiments provided herein is a method of treating pain, the method comprising administering into the subject

a pharmaceutical composition comprising multivesicular liposomes encapsulating bupivacaine phosphate, said multivesicular liposomes comprising

bupivacaine or a salt thereof;

phosphoric acid;

a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group; and,

optionally, a cholesterol and/or a plant sterol wherein said multivesicular liposomes are made by a process comprising:

a) preparing a first aqueous component comprising phosphoric acid;

b) preparing a lipid component comprising at least one organic solvent, at least one amphipathic lipid, and at least one neutral lipid lacking a hydrophilic head group;

c) mixing said first aqueous component and said lipid component to form a water-in-oil emulsion, wherein at least one component comprises bupivacaine or a salt thereof;

d) mixing said water-in-oil emulsion with a second aqueous component to form solvent spherules; and

e) removing the organic solvent from the solvent spherules to form multivesicular liposomes encapsulating bupivacaine phosphate,

wherein inadvertent administration of the pharmaceutical composition into the vasculature of the subject does not result in cardiac side effects or CNS side effects in the subject.

The present disclosure is directed to formulations and methods for treating or preventing head pain, including migraines, with dihydroergotamine mesylate.

A method of producing a composition for a treatment of cardiovascular and cerebrovascular diseases is provided. The method includes the following steps of: a) according to a ratio of 1 lt, adding 2 ml 36.5-37.5% formic aldehyde solution to 998 ml sterile and 0.85-0.95% isotonic sodium chloride solution to obtain a mixture, mixing the mixture thoroughly and obtaining an aldehyde solution with a final concentration of 0.073-0.075% by weight for injection, and b) storing the composition obtained in a dark place at a temperature of 15-35° C.

The invention provides novel compounds, compositions and formulations of liposomes, microbubbles and/or nanodroplets, and emulsions thereof, that are useful in delivery of various nucleic acids and genes (e.g., single stranded RNA, DNA, si-RNA and CRISPR constructs), as well as methods of preparation and use thereof including methods of imaging and gene delivery using ultrasound activation.

In some embodiments provided herein is a method of treating pain, the method comprising injecting into the subarachnoid space of the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

A method of protecting a respiratory tract or a lung from damage is provided. The method comprises administering a pharmaceutical composition to a patient in need thereof. The pharmaceutical composition comprises trehalose or a trehalose derivative.

The present disclosure provides an anti-tumor polypeptide Bax-BH3, a fluorescent polymeric nanomicelle, a preparation method and use thereof, belonging to the technical field of medicines. The anti-tumor polypeptide Bax-BH3 has an amino acid sequence set forth in SEQ ID No: 1; the fluorescent polymeric nanomicelle includes the anti-tumor polypeptide Bax-BH3 and a polymer carrier; and the polymer carrier is a block copolymer RGD-PHPMA-b-Poly(MMA-alt-(Rhob-MA)). In the present disclosure, the anti-tumor polypeptide Bax-BH3 has desirable biocompatibility and biological activity; and the fluorescent polymeric nanomicelle encapsulates the anti-tumor polypeptide Bax-BH3 by the block copolymer RGD-PHPMA-b-Poly(MMA-alt-(Rhob-MA)), with high encapsulation rate and drug loading, and good release performance.

Described is an aqueous calcium gluconate solution formulated without calcium saccharate, which can be stored in a flexible plastic bag and can be terminally sterilized.

The present disclosure provides a compositions and methods of inhibiting O.sup.6-methylguanine DNA methyltransferase in human tumor cells by providing an effective amount of an agent that directly or indirectly inhibits the O.sup.6-methylguanine DNA methyltransferase in a pharmaceutically acceptable carrier, wherein the amount is effective to potentiate an anti-tumor activity of one or more alkylating agents, platinum drugs, or antimetabolites, wherein tumor cells are triggered into programmed cell death.